https://doi.org/10.55788/dab1d220
“There is a need for simple, low-cost, scalable treatment strategies for patients with hypertension in Africa,” according to Dr Dike Ojji (Abuja University, Nigeria) [1]. “Most patients still receive only 1 anti-hypertensive agent, while guidelines recommend that patients should receive at least 2 agents.”
The investigator-initiated VERONICA-Nigeria trial randomised 300 self-identified Black African adults with uncontrolled hypertension from Nigeria 1:1 to a single 3-drug pill-based treatment protocol with a low-dose combination of telmisartan, amlodipine, and indapamide, or to the standard-of-care Nigerian hypertension treatment protocol, which starts with 1 agent (i.e. amlodipine) and may be changed to 2 agents if the result is insufficient. Prof. Ojji and colleagues looked at the change in home-measured systolic BP at 6 months.
After 6 months of treatment, participants in the 3-drug pill/GMRx2 group had an average 5.8 mmHg lower systolic BP than those in the standard-of-care group. For diastolic BP, the corresponding difference was -3.6 mmHg. Furthermore, 62% of the participants in the experimental arm versus 28% of those in the control arm had achieved a BP <130/80 mmHg (P<0.001).
“No patients in either study arm had discontinued treatment due to adverse events,” continued Dr Ojji. “The only safety issue we noticed was a slight increase in hypo-potassium (<3.5 mmol/L) in the GMRx2 arm (34% vs 18%).” When the researchers looked at participants with a potassium level <3.0 mmol/L, they noticed that the proportion had dropped from 34% to 9% in the experimental arm.
In conclusion, the single 3-drug pill protocol was more effective than the standard-of-care BP protocol in lowering BP in Black African patients. The BP control rate at 1 month was 80%, which was maintained throughout the study.
Relevant reading:
- Ojji D, et al. VERONICA-Nigeria - deliVERy of Optimal blood pressure coNtrol in afrICA. HOTLINE 2, ESC Congress 2024, 30 Aug–02 Sept, London, UK.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« FINEARTS-HF: Finerenone improves outcomes in heart failure with preserved ejection fraction Next Article
Is administering BP medication in the evening better than in the morning? »
« FINEARTS-HF: Finerenone improves outcomes in heart failure with preserved ejection fraction Next Article
Is administering BP medication in the evening better than in the morning? »
Table of Contents: ESC 2024
Featured articles
Meet the Expert: Dr Abdullahi Mohamed on Iron Deficiency in Patients with HF
2024 ESC Guidelines in a Nutshell
Guidelines for the management of elevated blood pressure and hypertension
Guidelines for the management of chronic coronary syndromes
Guidelines for the management of atrial fibrillation
Guidelines for the management of peripheral artery and aortic diseases
Crossing Borders in Arrhythmia
EPIC-CAD: What is the best antithrombotic approach in high-risk AF plus stable CAD?
OCEANIC-AF: Asundexian inferior to apixaban for ischaemic stroke prevention in AF
MIRACLE-AF: Elegant solution to improve AF care in rural China
SUPPRESS-AF: What is the value of adding LVA ablation to PVI in AF?
Clever Ideas for Coronary Artery Disease
ABYSS: Can beta-blocker safely be interrupted post-MI?
SWEDEGRAFT: Can a no-touch vein harvesting technique improve outcomes in CABG?
Bioadaptor meets expectations in reducing target lesion failures in coronary artery disease
REC-CAGEFREE I: Can we avoid permanent stenting with drug-coated balloons?
OCCUPI: OCT-guided PCI improves outcomes in complex CAD
Highway to Hypertension Control
Low-dose 3-drug pill GMRx2 shows promise in lowering BP
Is administering BP medication in the evening better than in the morning?
VERONICA: Improving BP control in Africa with a simple strategy
High-end Trials in Heart Failure
FINEARTS-HF: Finerenone improves outcomes in heart failure with preserved ejection fraction
MRAs show varied efficacy in heart failure across ejection fractions
MATTERHORN: Transcatheter repair matches surgery for HF with secondary mitral regurgitation
RESHAPE-HF2: Not a “tie-breaker” for TEER in heart failure
Practical Gains in Screening and Diagnostics
STEEER-AF: Shockingly low adherence to ESC atrial fibrillation guidelines
SCOFF: To fast or not to fast, that’s the question
WESTCOR-POC: Point-of-care hs-troponin testing increases emergency department efficiency
PROTEUS: Can AI improve decision-making around stress echocardiography?
RAPIDxAI: Can AI-augmented chest pain assessment improve cardiovascular outcomes?
Miscellaneous Achievements in Cardiology
HELIOS-B: Vutrisiran candidate for SoC in ATTR cardiomyopathy
Does RAS inhibitor discontinuation affect outcomes after non-cardiac surgery?
Novel approach to managing severe tricuspid regurgitation proves its value
NOTION-3: TAVI plus PCI improves outcomes in CAD plus severe aortic stenosis
RHEIA: TAVI outperformed surgery in women with aortic stenosis
Related Articles
November 7, 2024
HELIOS-B: Vutrisiran candidate for SoC in ATTR cardiomyopathy
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com